ESCC
MCID: ESP027
MIFTS: 58

Esophagus Squamous Cell Carcinoma (ESCC)

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Esophagus Squamous Cell Carcinoma

MalaCards integrated aliases for Esophagus Squamous Cell Carcinoma:

Name: Esophagus Squamous Cell Carcinoma 11 14
Esophageal Squamous Cell Carcinoma 58 5 43 16
Squamous Cell Carcinoma of the Esophagus 58
Squamous Cell Carcinoma of Esophagus 71
Oesophagus Squamous Cell Carcinoma 11
Esophageal Squamous-Cell Carcinoma 75
Esophageal Epidermoid Carcinoma 58
Squamous Cell Esophageal Cancer 53
Scc of Oesophagus 11
Scc of Esophagus 11
Escc 58

Characteristics:


Inheritance:

Squamous Cell Carcinoma of the Esophagus: Multigenic/multifactorial 58

Prevelance:

Squamous Cell Carcinoma of the Esophagus: 1-9/100000 (Europe, Europe, Europe, Worldwide, Austria, Belgium, Croatia, Czech Republic, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-9/1000000 (Bulgaria) 58

Age Of Onset:

Squamous Cell Carcinoma of the Esophagus: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 11 DOID:3748
MeSH 43 D000077277
NCIt 49 C4024
SNOMED-CT 68 276804009
ICD10 via Orphanet 32 C15.0 C15.1 C15.3 more
UMLS via Orphanet 72 C0279626
Orphanet 58 ORPHA99977
ICD11 33 1417891145
UMLS 71 C0279626

Summaries for Esophagus Squamous Cell Carcinoma

Orphanet: 58 Esophageal squamous cell carcinoma (ESCC) is a type of esophageal carcinoma (EC; see this term) that can affect any part of the esophagus, but is usually located in the upper or middle third.

MalaCards based summary: Esophagus Squamous Cell Carcinoma, also known as esophageal squamous cell carcinoma, is related to squamous cell carcinoma and esophageal cancer. An important gene associated with Esophagus Squamous Cell Carcinoma is MIR296 (MicroRNA 296). The drugs Trioxsalen and Cobalt have been mentioned in the context of this disorder. Affiliated tissues include esophagus, lymph node and testis, and related phenotypes are feeding difficulties in infancy and clinodactyly of the 5th toe

Disease Ontology: 11 An esophageal carcinoma that derives from epithelial squamous cells located in the esophagus.

Wikipedia: 75 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophagus Squamous Cell Carcinoma

Diseases related to Esophagus Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 31.5 MALAT1 LINC01233 HOTAIR EPIST CASC9
2 esophageal cancer 31.2 MIR296 MEG3 MALAT1 HOTAIR GAS5 CASC9
3 thyroid carcinoma 31.1 MALAT1 HOTAIR GAS5 AFAP1-AS1
4 oral squamous cell carcinoma 31.0 MIR296 MEG3 MALAT1 HOTAIR CCAT1
5 retinoblastoma 30.9 MEG3 MALAT1 HOTAIR CCAT1 BANCR
6 gastric cardia adenocarcinoma 30.9 MEG3 HOTAIR EPIST
7 gastrointestinal system cancer 30.9 MIR296 MALAT1 HOTAIR BANCR
8 small cell cancer of the lung 30.7 MALAT1 HOTTIP HOTAIR
9 pancreatic ductal adenocarcinoma 30.6 MALAT1 HOTTIP HOTAIR AFAP1-AS1
10 laryngeal squamous cell carcinoma 30.6 MALAT1 HOXA11-AS HOTAIR CCAT1
11 thyroid cancer, nonmedullary, 1 30.6 MEG3 MALAT1 LINC-ROR HOTTIP HOTAIR BANCR
12 kidney cancer 30.5 MEG3 MALAT1 HOTAIR GAS5
13 bladder cancer 30.5 MEG3 MALAT1 HOTAIR GAS5 FOXD2-AS1 EPIST
14 myeloma, multiple 30.5 MEG3 MALAT1 HOTAIR GAS5 CCAT1
15 retinitis pigmentosa 11 30.4 MIR296 HOTAIR GAS5 CYTOR CCAT1
16 liver cirrhosis 30.4 MEG3 MALAT1 HOTAIR GAS5
17 ovarian epithelial cancer 30.4 MEG3 MALAT1 HOTAIR CCAT1
18 squamous cell carcinoma, head and neck 30.4 LUCAT1 HOTAIR EPIST CYTOR
19 cervical cancer 30.4 MEG3 MALAT1 HOXA11-AS HOTAIR GAS5 CCAT1
20 vulva squamous cell carcinoma 30.4 MEG3 MALAT1
21 hepatocellular carcinoma 30.4 MIR296 MEG3 MALAT1 LINC-ROR HOXA11-AS HOTTIP
22 leukemia, acute myeloid 30.4 MIR296 MEG3 MALAT1 HOTAIR CCAT1
23 nasopharyngeal carcinoma 30.2 MIR296 MEG3 MALAT1 LINC00460 LINC-ROR HOTAIR
24 lung cancer susceptibility 3 30.2 MIR296 MEG3 MALAT1 LINC-ROR HOTAIR GAS5
25 renal cell carcinoma, nonpapillary 30.2 MIR296 MEG3 MALAT1 LUCAT1 LINC-ROR HOTAIR
26 gallbladder cancer 30.2 MEG3 MALAT1 LINC-ROR HOTAIR CYTOR CCAT1
27 pancreatic cancer 30.1 MEG3 MALAT1 LINC-ROR HOTTIP HOTAIR GAS5
28 osteogenic sarcoma 30.0 MEG3 MALAT1 LUCAT1 HOXA11-AS HOTTIP HOTAIR
29 gastric cancer 29.9 MEG3 MALAT1 LINC-ROR HOXA11-AS HOTTIP HOTAIR
30 glioma 29.9 MIR296 MEG3 MALAT1 LUCAT1 HOXA11-AS HOTTIP
31 ovarian cancer 29.9 MIR296 MEG3 MALAT1 LUCAT1 LINC-ROR HOXA11-AS
32 melanoma 29.9 MEG3 MALAT1 LINC-ROR HOTAIR GAS5 BANCR
33 lung cancer 29.7 MIR296 MEG3 MALAT1 LUCAT1 LINC00460 LINC-ROR
34 colorectal cancer 29.6 MIR296 MEG3 MALAT1 LINC00460 LINC-ROR HOXA11-AS
35 tylosis with esophageal cancer 11.3
36 basaloid squamous cell carcinoma 10.8
37 esophagitis 10.7
38 neutropenia 10.6
39 immunodeficiency, common variable, 10 10.6
40 achalasia 10.5
41 thoracic cancer 10.5
42 factor viii deficiency 10.5
43 head and neck cancer 10.5
44 pituitary tumors 10.5
45 factor vii deficiency 10.5
46 adenoid cystic carcinoma 10.5
47 ataxia-telangiectasia 10.5
48 xeroderma pigmentosum, variant type 10.5
49 telangiectasis 10.5
50 chromosome 18p deletion syndrome 10.4

Graphical network of the top 20 diseases related to Esophagus Squamous Cell Carcinoma:



Diseases related to Esophagus Squamous Cell Carcinoma

Symptoms & Phenotypes for Esophagus Squamous Cell Carcinoma

Human phenotypes related to Esophagus Squamous Cell Carcinoma:

58 30 (show all 8)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 feeding difficulties in infancy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008872
2 clinodactyly of the 5th toe 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001864
3 esophageal carcinoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011459
4 nausea and vomiting 58 30 Frequent (33%) Frequent (79-30%)
HP:0002017
5 abnormality of the voice 58 30 Frequent (33%) Frequent (79-30%)
HP:0001608
6 cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0012735
7 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
8 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002716

Drugs & Therapeutics for Esophagus Squamous Cell Carcinoma

Drugs for Esophagus Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trioxsalen Approved Phase 3 3902-71-4 5585
2
Cobalt Approved, Experimental, Withdrawn Phase 3 7440-48-4 104729
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
5
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
6
Nedaplatin Approved, Investigational Phase 3 95734-82-0
7
Durvalumab Approved, Investigational Phase 3 1428935-60-7
8
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
9
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
10
Tannic acid Approved Phase 3 1401-55-4 16129878 16129778
11
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
12
Nivolumab Approved Phase 3 946414-94-4
13
Ipilimumab Approved Phase 3 477202-00-9
14
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
15
Fluorouracil Approved Phase 3 51-21-8 3385
16
Panitumumab Approved, Investigational Phase 3 339177-26-3
17
Dihematoporphyrin ether Investigational Phase 3 97067-70-4
18
Diethyl ether Experimental Phase 3 60-29-7 3283
19
3,4-Dihydroxycinnamic Acid Experimental, Investigational Phase 3 331-39-5, 501-16-6 689043
20
Andrographolide Investigational Phase 3 5508-58-7 343585
21 Photosensitizing Agents Phase 3
22 Hematoporphyrins Phase 3
23 Hematoporphyrin Derivative Phase 3
24 Dermatologic Agents Phase 3
25 Tea Phase 3
26 Antioxidants Phase 3
27
Megestrol Phase 3 3562-63-8 3080587 19090
28 Antineoplastic Agents, Hormonal Phase 3
29 Contraceptives, Oral, Hormonal Phase 3
30 Contraceptives, Oral Phase 3
31 Contraceptive Agents Phase 3
32 topoisomerase I inhibitors Phase 3
33 Analgesics Phase 3
34 Antirheumatic Agents Phase 3
35 Platelet Aggregation Inhibitors Phase 3
36 Anti-Inflammatory Agents, Non-Steroidal Phase 3
37 Analgesics, Non-Narcotic Phase 3
38 Anti-Inflammatory Agents Phase 3
39 Antiviral Agents Phase 3
40 Antiprotozoal Agents Phase 3
41 Antiparasitic Agents Phase 3
42 Andrographis Phase 3
43 Chirata Phase 3
44 Vitamins Phase 3
45 Trace Elements Phase 3
46 Antidotes Phase 3
47 Micronutrients Phase 3
48 Protective Agents Phase 3
49 Hormones Phase 3
50 Calcium, Dietary Phase 3

Interventional clinical trials:

(show top 50) (show all 425)
# Name Status NCT ID Phase Drugs
1 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
2 Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer Unknown status NCT02025036 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
3 Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer Unknown status NCT02607540 Phase 3
4 Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy Unknown status NCT02603159 Phase 3 Capecitabine(Aibin)
5 A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma Unknown status NCT02570893 Phase 3 Paclitaxel and carboplatin
6 An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma Unknown status NCT02677597 Phase 3 Cisplatin Combined With S-1;Cisplatin Combined With Paclitaxel
7 Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study Unknown status NCT02319187 Phase 3 S1;S-1;irinotecan
8 A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma Unknown status NCT02409186 Phase 3 Nimotuzumab;chemoradiotherapy Paclitaxel;chemoradiotherapy Cisplatin
9 A Randomized Phase II Trial Evaluating The Addition Of Nimotuzumab To Chemoradiation For Patients With Esophageal Squamous Cell Carcinoma After Radical Esophagectomy Who Suffer With Lymph Nodes Recurrence Unknown status NCT01402180 Phase 2, Phase 3 chemotherapy
10 Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma Unknown status NCT02891083 Phase 3 Adjuvant chemotherapy (Paclitaxel and Cisplatin)
11 Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma; Unknown status NCT01745107 Phase 3
12 Is Elective Nodal Irradiation (ENI) Necessary For Patients With Thoracic Esophageal Squamous Cell Carcinoma Who Undergo Esophagectomy And With Pathological Stage Of T1-2,N+,M0 -- A Randomized Phase Ⅲ Trial Unknown status NCT01398449 Phase 3
13 Chemoprevention of Esophageal Squamous Cell Carcinoma With Aspirin and Tea Polyphenols: a Randomized Controlled Trial. Unknown status NCT01496521 Phase 3 Aspirin
14 Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial Unknown status NCT02604615 Phase 3 Capecitabine(Aibin);Oxaliplatin(Aiheng)
15 An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas Unknown status NCT02611700 Phase 3 Nimotuzumab;Paclitaxel;Cisplatin;Placebo
16 GASC1 Inhibitor Caffeic Acid for Advanced Squamous Esophageal Cell Cancer (ESCC): a Multicenter, Phase II Trial (GiCAEC) Unknown status NCT04648917 Phase 3 Caffeic acid
17 Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Unknown status NCT02375997 Phase 3
18 Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy Completed NCT02644408 Phase 3 Megestrol(Yining)
19 A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Completed NCT02399306 Phase 3 Enteral nutrition
20 A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma Completed NCT02395705 Phase 3 cisplatin and paclitaxel
21 A Phase III Randomized Clinical Trial of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma Completed NCT01591135 Phase 3 Paclitaxel plus 5-fluorouracil;Cisplatin plus 5-fluorouracil
22 A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial Completed NCT02459457 Phase 3 Paclitaxel and Cisplatin;Paclitaxel and Fluorouracil;Paclitaxel and Carboplatin
23 A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer Completed NCT01137123 Phase 3 adjuvant chemotherapy
24 The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer Completed NCT04196075 Phase 3 Andrographis Paniculata
25 A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181) Completed NCT02564263 Phase 3 paclitaxel;docetaxel;irinotecan
26 A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181) Completed NCT03933449 Phase 3 paclitaxel;docetaxel;irinotecan
27 S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study Completed NCT02813967 Phase 3 S-1
28 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
29 Neoadjuvant Immunotherapy Combined With Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (cII-III Stage): A Multi-center Prospective Randomized Clinical Trial Recruiting NCT04973306 Phase 2, Phase 3 Tislelizumab
30 Adjuvant Esophagectomy Versus Chemoradiation for Patients With Clinical Stage N0 and Pathological Stage T1b (After Endoscopic Submucosal Dissection, ESD) Esophageal Squamous Cell Carcinoma (Ad-ESD Trial): a Multicentric, Open Label, Randomized Trial Recruiting NCT04135664 Phase 3
31 A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15) Recruiting NCT03748134 Phase 3 Placebo;Cisplatin;Paclitaxel;Fluorouracil
32 Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903) Recruiting NCT04138212 Phase 3 Paclitaxel, Cisplatin
33 A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) Recruiting NCT04550260 Phase 3 Durvalumab;Placebo;cisplatin + fluorouracil;cisplatin + capecitabine
34 A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Recruiting NCT04280822 Phase 3 Neoadjuvant immunochemotherapy
35 A Randomized Phase Ⅱ/Ⅲ Trial of Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT03600831 Phase 2, Phase 3 Docetaxel plus cisplatin
36 NEoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed (NEEDS Trial) Recruiting NCT04460352 Phase 3 Carboplatin, paclitaxel;Cisplatin, paclitaxel;Oxaliplatin, calcium folinate, 5-fluorouracil
37 Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial Recruiting NCT02461043 Phase 3 paclitaxel; cisplatin
38 Multicenter Prospective Randomized Controlled Study of Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone in the Treatment of pN1-2 (pT1b-3N1-2M0) Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT04009265 Phase 3
39 A Randomized Phase II/III Study of Paclitaxel/Cisplatin Versus Cisplatin/5-fluorouracil in Neoadjuvant Chemoradiation Followed by Surgery for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) Recruiting NCT03623737 Phase 2, Phase 3 neoadjuvant chemoradiation
40 A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002) Recruiting NCT04807673 Phase 3 Paclitaxel;Cisplatin
41 A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma Recruiting NCT04848753 Phase 3
42 Lerotinib Versus Investigator's Choice Single-agent Chemotherapy in Patients With Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma and EGFR Overexpression That Progressed After Second-line Therapy:Phase 3 Study Recruiting NCT04415853 Phase 3 Lerotinib;Irinotecan/Tegafur
43 A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT02465736 Phase 3 Docetaxel;Cisplatin;Vinorelbine
44 A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma Recruiting NCT05213312 Phase 2, Phase 3 Nivolumab;Cisplatin;Paclitaxel;5Fluorouracil
45 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-TIGIT Antibody) in Patients With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy Recruiting NCT04543617 Phase 3 Tiragolumab;Atezolizumab;Tiragolumab Matching Placebo;Atezolizumab Matching Placebo
46 Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma Recruiting NCT05357846 Phase 3 Sintilimab;Paclitaxel;Cisplatin
47 A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) Recruiting NCT04210115 Phase 3 placebo;cisplatin;5-FU;leucovorin;levoleucovorin;oxaliplatin
48 A Phase III Study of Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma Recruiting NCT03790553 Phase 3
49 A Randomized Controlled Phase III Trial of Comparing Local Field With Additional Prophylactic Irradiation in Chemoradiotherapy for Clinical-T1bN0M0 Esophageal Cancer Recruiting NCT04328948 Phase 3
50 A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma Recruiting NCT04949256 Phase 3 Pembrolizumab;Lenvatinib;Cisplatin;5-FU;Oxaliplatin;Leucovorin;Levoleucovorin;Paclitaxel

Search NIH Clinical Center for Esophagus Squamous Cell Carcinoma

Cochrane evidence based reviews: esophageal squamous cell carcinoma

Genetic Tests for Esophagus Squamous Cell Carcinoma

Anatomical Context for Esophagus Squamous Cell Carcinoma

Organs/tissues related to Esophagus Squamous Cell Carcinoma:

FMA: Esophagus
MalaCards : Lymph Node, Testis, T Cells, Lung, Endothelial, Breast, Spinal Cord

Publications for Esophagus Squamous Cell Carcinoma

Articles related to Esophagus Squamous Cell Carcinoma:

(show top 50) (show all 13019)
# Title Authors PMID Year
1
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 5
25157968 2014
2
The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. 62 46
20485139 2010
3
Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. 53 62
17912028 2007
4
Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. 53 62
15968714 2005
5
[Flow cytometric detection and significance of four cyclins in esophageal cancer]. 53 62
15634523 2004
6
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11. 53 62
15132777 2004
7
Down-regulation of gut-enriched Kruppel-like factor expression in esophageal cancer. 53 62
12439907 2002
8
Endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma in patients with cirrhosis and esophageal varices. 62
35898831 2023
9
Mechanisms of function and clinical potential of exosomes in esophageal squamous cell carcinoma. 62
36328162 2023
10
Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. 62
36425536 2023
11
Controlling Nutritional Status Score Serves as a Prognosticator in Esophageal Squamous Cell Carcinoma: Optimal Timing of Evaluation of Patients Undergoing Neoadjuvant Treatment. 62
36197488 2023
12
Th1-involved immune infiltrates improve neoadjuvant chemoradiotherapy response of esophageal squamous cell carcinoma. 62
36279981 2023
13
Evaluation of Immunoexpression of AJUBA Protein in Normal Oral Mucosa and Oral Squamous Cell Carcinoma. 62
36222508 2023
14
Evodiamine inhibits ESCC by inducing M-phase cell-cycle arrest via CUL4A/p53/p21 axis and activating noxa-dependent intrinsic and DR4-dependent extrinsic apoptosis. 62
36265256 2023
15
N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. 62
36169023 2023
16
Azelnidipine may be a valuable drug for chemoprevention of ESCC with high MEK1/2 levels. 62
36420305 2022
17
Clonal relationship and alcohol consumption-associated mutational signature in synchronous hypopharyngeal tumours and oesophageal squamous cell carcinoma. 62
36261585 2022
18
Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma. 62
35930383 2022
19
Radiation Induced Liver Injury: Collateral Damage Radiologically Simulating Interval Metastasis in Carcinoma Esophagus; a Diagnostic Dilemma Resolved Through Liver Biopsy. 62
35470748 2022
20
Evaluation of Expression Of ADAM 10 as a Predictor of Lymph Node Metastasis in Oral Squamous Cell Carcinoma-An Immunohistochemical Study. 62
35771404 2022
21
Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. 62
34883083 2022
22
Analysis of the Amine Submetabolome Using Novel Isotope-Coded Pyrylium Salt Derivatization and LC-MS: Herbs and Cancer Tissues as Cases. 62
36473140 2022
23
Fusobacterium nucleatum induces MDSCs enrichment via activation the NLRP3 inflammosome in ESCC cells, leading to cisplatin resistance. 62
35435776 2022
24
Clinical impact of Fn-induced high expression of KIR2DL1 in CD8 T lymphocytes in oesophageal squamous cell carcinoma. 62
34935568 2022
25
Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients. 62
34253568 2022
26
Molecular characteristics of multifocal esophageal squamous cell carcinomas to discriminate multicentric origin from intramural metastasis. 62
36098222 2022
27
Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT? 62
36226869 2022
28
Using texture and colour enhancement imaging to evaluate gastrointestinal diseases in clinical practice: a review. 62
36420822 2022
29
ERK inhibitor: A candidate enhancing therapeutic effects of conventional chemo-radiotherapy in esophageal squamous cell carcinoma. 62
36470544 2022
30
Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study. 62
36473995 2022
31
Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine Computed Tomography Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models. 62
36018524 2022
32
ASO Visual Abstract: Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma Using Routine CT Imaging: Comparison of Size-Based Measurements and Radiomics-Based Models. 62
36068426 2022
33
ASO Author Reflections: NADPH Oxidase 2 has Potential as a Therapeutic Target for Esophageal Squamous Cell Carcinoma. 62
35986132 2022
34
ASO Author Reflections: Radiomics-Based Prediction of Individual Lymph Node Metastatic Status in Esophageal Squamous Cell Carcinoma. 62
35933539 2022
35
ASO Visual Abstract: NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma. 62
36002704 2022
36
Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery. 62
36456150 2022
37
Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. 62
36454568 2022
38
A more novel and robust gene signature predicts outcome in patients with esophageal squamous cell carcinoma. 62
36265781 2022
39
High endothelial venules associated with better prognosis in esophageal squamous cell carcinoma. 62
36272333 2022
40
A matched cohort comparison of endoscopic resection, chemoradiation and esophagectomy in the treatment of early-stage esophageal squamous cell carcinoma. 62
36473738 2022
41
Addendum: Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma. 62
36473119 2022
42
Genetic variant in miR-17-92 cluster binding sites is associated with esophageal squamous cell carcinoma risk in Chinese population. 62
36461008 2022
43
The prognostic value of positron emission tomography/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy. 62
36345769 2022
44
CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. 62
36427397 2022
45
Esophageal squamous cell carcinoma darkly stained with iodine. 62
36458865 2022
46
NADPH Oxidase 2 Has a Crucial Role in Cell Cycle Progression of Esophageal Squamous Cell Carcinoma. 62
35972670 2022
47
Traction-assisted circumferential endoscopic submucosal dissection of early esophageal squamous cell carcinoma, followed by metal stent insertion and fixation with a dedicated clip. 62
35180786 2022
48
Comment on: "Is Adjuvant Therapy a Better Option for Esophageal Squamous Cell Carcinoma Patients Treated With Esophagectomy? A Prognosis Prediction Model Based on Multicenter Real-world Data". 62
35129491 2022
49
MicroRNAs in esophageal squamous cell carcinoma: Application in prognosis, diagnosis, and drug delivery. 62
36356334 2022
50
TWIST1 activates cancer stem cell marker genes to promote epithelial-mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma. 62
36474162 2022

Variations for Esophagus Squamous Cell Carcinoma

ClinVar genetic disease variations for Esophagus Squamous Cell Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.2198C>T (p.Pro733Leu) SNV Likely Pathogenic
376076 rs121913446 GRCh37: 7:55242428-55242428
GRCh38: 7:55174735-55174735
2 CTNNB1 NM_001904.4(CTNNB1):c.94G>A (p.Asp32Asn) SNV Likely Pathogenic
376228 rs28931588 GRCh37: 3:41266097-41266097
GRCh38: 3:41224606-41224606

Cosmic variations for Esophagus Squamous Cell Carcinoma:

8 (show top 50) (show all 11188)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM142081527 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.1006+2T>A p.? 19:58086172-58086172 18
2 COSM140961271 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 19:58086172-58086172 18
3 COSM109468109 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.433+2T>A p.? 19:58086172-58086172 18
4 COSM86897778 ZSCAN18 oesophagus,NS,carcinoma,squamous cell carcinoma c.838+2T>A p.? 19:58086172-58086172 18
5 COSM98059731 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 20:59191624-59191624 18
6 COSM149923539 ZNF831 oesophagus,NS,carcinoma,squamous cell carcinoma c.605T>C p.L202P 20:59191624-59191624 18
7 COSM88515958 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.938C>G p.S313C 17:82831517-82831517 18
8 COSM88515712 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.668C>G p.S223* 17:82831787-82831787 18
9 COSM138690836 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-31C>G p.? 17:82831517-82831517 18
10 COSM88513307 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.170C>G p.S57* 17:82832285-82832285 18
11 COSM88514972 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.80G>C p.C27S 17:82832375-82832375 18
12 COSM138689938 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-889G>C p.? 17:82832375-82832375 18
13 COSM138689466 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-201C>G p.? 17:82831687-82831687 18
14 COSM138688764 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-799C>G p.? 17:82832285-82832285 18
15 COSM88514017 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.777C>A p.Y259* 17:82831678-82831678 18
16 COSM88515841 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.37C>A p.H13N 17:82832418-82832418 18
17 COSM138689254 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-192C>A p.? 17:82831678-82831678 18
18 COSM88514274 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.768C>G p.Y256* 17:82831687-82831687 18
19 COSM138690667 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-301C>G p.? 17:82831787-82831787 18
20 COSM138690762 ZNF750 oesophagus,NS,carcinoma,squamous cell carcinoma c.-229-932C>A p.? 17:82832418-82832418 18
21 COSM90465117 ZNF548 oesophagus,NS,carcinoma,squamous cell carcinoma c.1016A>C p.H339P 19:57399267-57399267 18
22 COSM93683971 ZNF548 oesophagus,NS,carcinoma,squamous cell carcinoma c.980A>C p.H327P 19:57399267-57399267 18
23 COSM102366084 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 18
24 COSM102372996 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 18
25 COSM104733716 ZNF365 oesophagus,NS,carcinoma,squamous cell carcinoma c.712G>A p.E238K 10:62376905-62376905 18
26 COSM109217250 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 19:44008861-44008861 18
27 COSM139548867 ZNF230 oesophagus,NS,carcinoma,squamous cell carcinoma c.87G>C p.Q29H 19:44008861-44008861 18
28 COSM100770466 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1117C>T p.R373W 17:32369340-32369340 18
29 COSM100755139 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1210C>T p.R404W 17:32369340-32369340 18
30 COSM90696431 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1219C>T p.R407W 17:32369340-32369340 18
31 COSM139216379 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1210C>T p.R404W 17:32369340-32369340 18
32 COSM91133838 ZNF207 oesophagus,NS,carcinoma,squamous cell carcinoma c.1162C>T p.R388W 17:32369340-32369340 18
33 COSM131330822 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
34 COSM94832002 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
35 COSM88860826 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
36 COSM88887411 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.86A>T p.E29V 23:152919042-152919042 18
37 COSM89189081 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.71A>T p.E24V 23:152919042-152919042 18
38 COSM94818098 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
39 COSM129903764 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
40 COSM112129853 ZNF185 oesophagus,NS,carcinoma,squamous cell carcinoma c.491A>T p.E164V 23:152919042-152919042 18
41 COSM125164549 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9439C>T p.P3147S 8:76863231-76863231 18
42 COSM125167660 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6188C>A p.P2063H 8:76853187-76853187 18
43 COSM127363671 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.2120C>G p.S707C 8:76706208-76706208 18
44 COSM127389059 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10574C>T p.S3525F 8:76864288-76864288 18
45 COSM127376736 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.4099G>A p.D1367N 8:76851020-76851020 18
46 COSM127405081 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.439G>T p.E147* 8:76704527-76704527 18
47 COSM125134824 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6767G>A p.R2256Q 8:76853766-76853766 18
48 COSM127390973 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.9517C>T p.P3173S 8:76863231-76863231 18
49 COSM127363056 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.6845G>A p.R2282Q 8:76853766-76853766 18
50 COSM125162303 ZFHX4 oesophagus,NS,carcinoma,squamous cell carcinoma c.10496C>T p.S3499F 8:76864288-76864288 18

Expression for Esophagus Squamous Cell Carcinoma

Search GEO for disease gene expression data for Esophagus Squamous Cell Carcinoma.

Pathways for Esophagus Squamous Cell Carcinoma

GO Terms for Esophagus Squamous Cell Carcinoma

Sources for Esophagus Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....